Article
Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Aug 2021
Loree Jonathan M, Wang Yucai, Syed Muddassir A, Sorokin Alexey V, Coker Oluwadara, Xiu Joanne, Weinberg Benjamin A, Vanderwalde Ari M, Tesfaye Anteneh, Raymond Victoria M, Miron Benjamin, Tarcic Gabi, Zelichov Ori, Broaddus Russell R, Ng Patrick Kwok Shing, Jeong Kang Jin, Tsang Yiu Huen, Mills Gordon B, Overman Michael J, Grothey Axel, Marshall John L, Kopetz Scott
Abstract excerpt
PURPOSE: Mutations in KRAS/NRAS (RAS) predict lack of anti-EGFR efficacy in metastatic colorectal cancer (mCRC). However, it is unclear if all RAS mutations have similar impact, and atypical mutations beyond those in standard guidelines exist. EXPERIMENTAL DESIGN: We reviewed 7 tissue and 1 cell-free DNA cohorts of 9,485 patients to characterize atypical RAS variants. Using an in vitro cell-based assay...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
